SlideShare a Scribd company logo
1 of 25
Download to read offline
Biological Threats:
Dealing with COVID in
the Workplace
June 2020
Presenter: Doug Kube, EP, CHSC
dougkube@outlook.com
Introductions
2
Presenter & Facilitator:
 Doug has worked for 30 years' in safety, occupational and public health.
 He has worked in a variety of sectors including pharmaceutical, food,
aviation/aerospace, courier/mail, chemical and consulting engineering.
 Doug was Senior Director, Health, Safety & Environment at Sanofi Pasteur
Toronto where he was responsible for the biological safety and bio-
containment program at its containment level 2 and 3 vaccine
manufacturing, research and development site.
 He was part Air Canada’s team that led the response to the 2010 H1N1
influenza pandemic and part of Purolator’s 2003 SARS response team.
 He has completed post-graduate courses in High Level Biocontainment for
Healthcare Facilities at University of Nebraska, Epidemics: Dynamics of
Infectious Diseases at Penn State University, Emerging Infectious Diseases
at Johns Hopkins Bloomberg School of Public Health and Epidemiology at
University of Ottawa.
Doug Kube, EP, CHSC
dougkube@outlook.com
Ph. 705-994-7053
Presentation Overview
We will cover the following:
 Recognizing threats of COVID-19 and return to work
 Preventing workplace outbreaks, work refusals or
disruptions and assuring compliance
 Benefits of a risk management approach
 Biological safety and risk assessment fundamentals
 COVID-19 Biological Risk Assessment Tool for scenarios
associated with specific workplaces and jobs
3
4
5
COVID-19 Safety Plan
Does your plan include all these controls?
• Work from home
• Postpone projects
• Stop meeting face to face
• Physical distancing of 2 m
• Wear face coverings or masks
• Medical screening of visitors & workers
• Reschedule unnecessary visits
• Train everyone on possible hazards
• Train people on how to keep surface clean
• Limit the # of people working in one space
• Have everyone wash their hands
• Reposition workstations to increase distances
• Control # of people in workplace at one time, who they speak to, what they handle
• Clean and disinfect workplace thoroughly and frequently
• Keep COVID-19 awareness, safety talk, while maintaining a safe physical distance
5
Cost of getting it wrong?
• Death (Global 361,270, U.S. 101,706, Cda 6,982)1
• Pain and suffering (Ontario 1,613 intensive care)
• Illness & serious illness (Hospitalized: NY 78,043, ON 8,152)
• Business interruption (40% Canadian retailers closed)
• Reduced morale
• More regulatory scrutiny, non-compliance
• Corporate reputation, employee and customer confidence
• Cost of workers compensation claims
• Divert management attention
• Lost business opportunity
1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU),
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6, taken 29May2020
Benefits of Risk Management
Approach to COVID-19
 ‘Stress test’ existing COVID-19 safety plans
 Workplace-specific assessment and inventory of:
 Key jobs/positions of concern
 Work locations with greatest risk
 Establish organizational risk profile and risk tolerance
 Enhanced, targeted risk controls to reduce transmission
 Increase organizational capacity to monitor and manage
 Confidence to employees, managers, Union, Boards
 Support existing crisis and business continuity plans
 Ensure compliance and due diligence
7
8
COVID-19 Biological Risk Assessment: Training & Risk Assessment
1. Pandemic
Status
2. Biosafety
Fundamentals
3. Risk
Assessment
Basics
4. Risk
Assessment
Tool
Virtual Risk
Assessment
Workshop
• Routes of transmission
• Decontamination and disinfection
• ISO 31000 standard for risk management,
• Identifying risk treatment and controls
• Using the Excel Tool to analyze and evaluate risk
• Job–specific, targeted risk controls
• Facilitate virtual, online assessment with Tool
• Analyze existing controls and evaluate effectiveness
• Identify additional preventative and protective measures
• Current pandemic situation
• Implications for business
9
Pandemic Status & Update
Case Demographic Distribution
https://ourworldindata.org/mortality-risk-covid, taken 29May2020
Case Fatality Rate by Age
 Case distribution equal in working adults
 Older age, especially > 65 yrs and people
with comorbidities appear more likely to
develop an infection and severe symptoms
and be at risk for death1
 In the U.S., obesity appears to be
emerging as a risk factor, BMI ≥ 30, in
nearly 1/2 of hospitalized patients1
 85% of Canadian cases in Ontario & Quebec
 Community-specific spread (hot spots)
1. Johns Hopkins ABX Guide, Paul G. Auwaerter, M.D., Coronavirus COVID-19 (SARS-CoV-2), Updated: May 23, 2020
Severe Acute Respiratory Syndrome
Corona-Virus 2 (SARS-CoV-2)
10
1. Ontario Health, Epidemiologic Summary, Confirmed cases (n=22,957) of COVID-19 by severity: Ontario, January 15, 2020 to May 17, 2020
2. Johns Hopkins ABX Guide, Paul G. Auwaerter, M.D., Coronavirus COVID-19 (SARS-CoV-2), Updated: May 23, 2020
 New strain not previously in humans
 Enveloped, positive-sense single-stranded RNA viruses
 Incubation period (exposure to symptom onset) 4 to 6 days
 Infectious 1 to 3 days before symptoms appear
 Peak viral load in pharynx ~4 days after infected
 Health effects:
 Older and those with underlying medical condition = high risk,
 95% of deaths in group 60+ years of age1
 Many infected have no symptoms (studies suggest up to 50%)2
Biological Safety Fundamentals
Routes of Transmission
 Droplets-borne: via droplets from the nose or mouth
spread when infected person sneezes or coughs
 Fomite: Indirect contact via droplet contaminated
surfaces. Touch surface, then eyes, nose or mouth
 Detectable on plastic and steel up to 3 days,
cardboard 1 day, copper 4 hours.
 Virus load reduces over time (half-life 5-6 hours)
 SARS-CoV-2 is an enveloped virus, therefore highly
susceptible to disinfectants
 Aerosol spread could occur, mostly in hospitals1
1. Johns Hopkins ABX Guide, Paul G. Auwaerter, M.D., Coronavirus COVID-19 (SARS-CoV-2), Updated: May 23, 2020
Biological Safety Fundamentals
What Increases Transmission Risk?
 Factors that affect risk:
1. People close to one another
2. Many people together (group gatherings)
3. Duration of interaction
 Successful Infection = Exposure to Virus x Time
4. Type of activity
 Talking quietly vs. cheering/shouting at sports event
5. Physical environment
 Layout? Degree of protection? Separation? Air flow
direction and volume? Air purification systems?
Close contact means: a face-to-face conversation for 15 minutes, or being in the same room for 2 hours
(Source: Ontario Self-Assessment website https://covid-19.ontario.ca/self-assessment/, taken 08May2020)
Biological Safety Fundamentals
Decontamination & Disinfection
 Enveloped virus = Highly susceptible to disinfectants
 Critical parameters for chemical disinfection: Type,
concentration, contact time and temperature
 Proven chemical disinfectants:
• 0.05% sodium hypochlorite (household bleach), dilute 1:100
• Alcohol (ethanol) at least 70%
• Hydrogen peroxide 0.5%
• Benzalkonium chloride >0.05% (less effective)
 Ultraviolet (UVC) light disinfection (30 mJ/cm2)*
13
* N95 Filtering Facepiece Respirator Ultraviolet Germicidal Irradiation (UVGI) Process for Decontamination and Reuse, University of Nebraska, Version Update 4/10/2020
Refer to manufacturer's specifications and instructions for proper concentration, contact time and temperature.
Risk Assessment
Fundamentals
We will cover the following:
 Risk management based on ISO
31000 standard
 Conducting risk assessments
 Assessing biological and
occupational health exposures
 Ascertaining risk tolerance
 Identifying risk treatment and
controls
14
Key Definitions
 Hazard - Source with a potential to cause injury and ill health. (ISO45001)
 The SARS-CoV-2 virus is a hazard
 Risk - The effect of uncertainty on objectives (ISO31000)
 Assessment of the consequences (illness) expressed in terms of
probability (likely, unlikely) and severity (mildly sick, death) is the risk.
 Becoming ill is one of the consequences of the hazard
 Risk Management - Coordinated activities to direct and control an
organization with regards to risk (ISO31000)
 The identification, analysis and elimination, and/or mitigation to an
acceptable level of risk
15
16
Risk Management
Why is it Important?
 One way to protect employees and the business
 Key part of H&S Management System
 Helps ensure business continuity
 Enables business to re-open, re-start or sustain operations
 Compliance requirement:
 WorkSafe British Columbia requires a COVID-19 Safety Plan be posted in
the workplace. “Step 1: Assess the risks at your workplace”
 Ontario “The employer is required to take every reasonable precaution
… and do a risk assessment to determine what parts of the jobsite and
what other workers the affected worker would have had contact with.”
 U.S. OSHA: "The employer shall assess the workplace to determine if
hazards are present, or are likely to be present, which necessitate the
use of personal protective equipment (PPE)."
Health & Safety Programs
Why do they need risk assessments?
Risk Assessments:
 Create awareness of hazards and risk.
 Identify who may be at risk.
 Prioritize risks and control methods.
 Determine the overall risk management plan an organization should develop.
 Determine if existing mitigation measures are adequate or if additional
measures are needed.
 Determine training needs.
17
Team!
 A team approach is needed
 Leader will facilitate the process
 Team needs to include subject matter
participants with knowledge and experience
necessary to assess the activity and risks
 Team provides expertise on the work and work
areas and envision ‘hazardous situations’
 Need more than H&S expertise
 Decisions to accept of residual risk may need
to be escalated to “decision maker”
18
19
Define the risk index and
tolerability
Define the level
of probability
Define the level
of severity
Is the risk index acceptable?
Can the risk be eliminated?
Can the risk be mitigated?
Can the residual risk be
accepted? (if any)
Take action
and continue
the operation
Health & safety concern is perceived
Identify hazards/consequences
and assess risks
NO
NO
NO
Cancel the
operation
YES
Take action
and continue
the operation
YES
Take action
and continue
the operation
YES
YES
Risk
Identification
Risk
Analysis
Risk
Evaluation
Risk
Treatment
(6.5)
RiskAssessment(6.4)
Risk Management as a Process
Risk Management
Risk Evaluation & Tolerance
Undesirable
Improvable
Acceptable
Unacceptable
and MUST have
more treatment
or controls
Acceptable with
current controls
but recommend
more treatment.
Acceptable as it
currently
stands, no
further action
As
Low
As
Reasonably
Practicable
Risk Treatment & Controls
 Risk Treatment: Process to modify risk
 Control: Measure that maintains or modifies risk
1. avoiding the risk by not to starting or continuing
with the activity that gives rise to the risk (no
face-to-face meetings, use Zoom or MS Teams);
2. removing the risk source (disinfecting surface);
3. changing the likelihood (shop less frequently);
4. changing the consequences (early medical care);
5. sharing the risk (buying insurance); and
6. retaining the risk by informed choice.
The Goal & “The Gold”
Risk Controls
Technical (engineering controls & PPE)
 HEPA air filtration of, plastic shields on cashier
stations, one-way aisle, surgical mask
Organizational / Administrative
 Physical distancing, personnel screening,
hygiene (cleaning & disinfection, handwashing)
close areas, work at home, Zoom meetings
Human / Behavioural
 Report when ill, sneeze/cough etiquette, train,
personnel screening, culture (managerial safety
visits, procedure use & adherence)
Technical (Engineering Controls)
Human (Behavioural Controls)
Organizational (Administrative Controls)
5 Step Process & Methodology
Questionnaire
Obtain site-specific
details, job risks,
community/worker
incidence, trends,
plan and
precautions
implemented to
date
Environmental
Scan
Review current
outbreak, known
transmission
dynamics,
geographic
distribution
Interview
Obtain site details,
understand work
environment,
stakeholders, local
guidance issued &
actioned to date
Training
Prepare participants
with knowledge and
understanding to
participate
Identify jobs and
potential hazard
situations and threats
to health, safety,
business continuity
Virtual, online
Risk Assessment
Analyze chosen jobs,
specific to exposure and
vulnerability
Use spreadsheet tool to
evaluate, consider
existing controls
Enable team to identify
targeted, additional
preventative and
protective measures
24
 RISK EVALUATION to support decision making
 GREEN = Acceptable, YELLOW = Improvable, RED = unacceptable,
 Do nothing, maintain existing controls, implement additional controls, stop activity
 Continual improvement: validate or assess the value of additional and new controls
Output
 RISK TREATMENT & CONTROLS: Additional and sustainable actions identified
and documented that can eliminate, reduce or mitigate the risk
 PREVENTION: avoid or reduce likelihood of exposure, and
 REDUCTION: reduce severity or impact, mitigate business losses
 Communication tool for case investigations, contact tracing, refusals, grievances
Severity Exposure
Frequency
Probability of
Scenario
Risk
Score
HSE CONCLUSION COMMENTS ACTION PLAN / ADDITIONAL RISK TREATMENT & CONTROLS
1. First Aid
5. Disabling illness (lost time)
15. Illness with medical treatment;
Minor business impact
25. Illness with hospitalization;
Significant business impact
50. Death; Major business impact
100. Multiple deaths; catastrophic
0.5. Very rarely
1. Rarely (known_
2. Unusual (1/mo-1/yr)
3. Occassional (1/wk-1/mo)
6. Frequently (~1/day)
10. Continuously, many/day
0.1 Practically impossible
0.5 Extremely remote
1. Remotely possible
3. Would be unusual
6. Quite possible (50/50)
10. Expected
Calculated. (Risk Level with
consideration for existing
controls).
Risk < 90 = Acceptable
90 - 270 = Improvable
> 270 = Undesirable/Action!
(Clarify any existing controls and note any relavent
facts or assumtions that may help in identifying risk
treatment or controls.)
(List and describe any additional actions or risk treatment (the process to modify risk) that can be taken to eliminate, reduce or mitigate
the risk. Risk Treatment or controls should consider preventing (avoiding or reducing likelhood of exposure) and reducing the severity.
Ensure you review all Proactive and Preventative Measures (Technical, Organizational and Human) listed in tab enstitled "Scoring Guide
& Measures")
15 3 6 270 Stores are encouraging customers to 'tap'
and signs posted indicating cash
transactions not recommended. Cashiers are
told to disinfect station, belt and ATM every
hour. But, hourly disinfection doesn't address
touching grocery items. May need to
consider accomodating vulnerable or at-risk
workers.
Improvable
1. Document COVID-19 safety plan to comply with provincial requirements.
2. Develop SOP for PPE, require cashiers to wear gloves when touching grocery items.
3. Develop cleaning/disinfection procedures for store and include cash stations.
4. Manager Safety Visits by managers to verify controls are implemented, talk to employees about their concerns,
coach them and provide caring safety culture.
5. Implement written SOP on safe handling/scanning of grocery items and include H&S precautions/controls
included from this risk risk assessment.
6. Implement HuP Tool - Procedure Use & Adherence with managers conducting hourly observations.
7. Implement process for more active personnel monitoring, screening and assessment.
ASSUMPTIONS:
Severity score (25) based on scenario of serious illness requiring hospitalization. NOTE: 4
vulnerable or at-risk employees known to work in area.
Exposure score (2), assuming that although cashier may touch items constantly, having an
infected customer and touching his/her items would be far less frequent or likely.
Probability score (3) assumes its unlikely the scenario would occur that leads to
hospitalization.
 Prioritize and ensure regulatory compliance = Due Diligence
THANK YOU!
For more information of assistance:
Doug Kube, EP, CHSC
dougkube@outlook.com
Ph. 705-994-7053

More Related Content

What's hot

Clinical Genomics and Medicine
Clinical Genomics and MedicineClinical Genomics and Medicine
Clinical Genomics and MedicineWarren Kibbe
 
Gut microbiome and host health
Gut microbiome and host health  Gut microbiome and host health
Gut microbiome and host health SANTHANAKUMARV
 
Gmo and environment
Gmo and environmentGmo and environment
Gmo and environmentsuperdomzky
 
Belmont Report - The Three Benchmark Rules
Belmont Report - The Three Benchmark RulesBelmont Report - The Three Benchmark Rules
Belmont Report - The Three Benchmark RulesClinosolIndia
 
One Health: Concept and applications
One Health: Concept and applicationsOne Health: Concept and applications
One Health: Concept and applicationsILRI
 
Precision Medicine - The Future of Healthcare
Precision Medicine - The Future of HealthcarePrecision Medicine - The Future of Healthcare
Precision Medicine - The Future of HealthcareData Science Thailand
 
Top 10 medical research interview questions and answers
Top 10 medical research interview questions and answersTop 10 medical research interview questions and answers
Top 10 medical research interview questions and answersJustinTimberlake999
 
Molecular mechanisms in crpc
Molecular mechanisms in crpcMolecular mechanisms in crpc
Molecular mechanisms in crpcAlok Gupta
 
Patient recruitment
Patient recruitmentPatient recruitment
Patient recruitmentswati2084
 
Building Ethics into the Research with Vulnerable groups
Building Ethics into the Research with Vulnerable groups Building Ethics into the Research with Vulnerable groups
Building Ethics into the Research with Vulnerable groups la71
 
Automate your literature monitoring for more effective pharmacovigilance
Automate your literature monitoring for more effective pharmacovigilanceAutomate your literature monitoring for more effective pharmacovigilance
Automate your literature monitoring for more effective pharmacovigilanceAnn-Marie Roche
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedLife Sciences Network marcus evans
 
Decentralized Clinical Trials, presentaiton by Craig Lipset for mHealth Israel
Decentralized Clinical Trials, presentaiton by Craig Lipset for mHealth IsraelDecentralized Clinical Trials, presentaiton by Craig Lipset for mHealth Israel
Decentralized Clinical Trials, presentaiton by Craig Lipset for mHealth IsraelLevi Shapiro
 
Introduction to biosafety
Introduction to biosafetyIntroduction to biosafety
Introduction to biosafetysumaiya nawaal
 
Developing Drugs in the New Era of Personalized Medicines
Developing Drugs in the New Era of Personalized Medicines Developing Drugs in the New Era of Personalized Medicines
Developing Drugs in the New Era of Personalized Medicines PAREXEL International
 
Ethics in Clinical Research: Challenges and Solutions
Ethics in Clinical Research: Challenges and SolutionsEthics in Clinical Research: Challenges and Solutions
Ethics in Clinical Research: Challenges and SolutionsClinosolIndia
 

What's hot (20)

Clinical Genomics and Medicine
Clinical Genomics and MedicineClinical Genomics and Medicine
Clinical Genomics and Medicine
 
Microbial resources
Microbial resourcesMicrobial resources
Microbial resources
 
Gut microbiome and host health
Gut microbiome and host health  Gut microbiome and host health
Gut microbiome and host health
 
Gmo and environment
Gmo and environmentGmo and environment
Gmo and environment
 
Belmont Report - The Three Benchmark Rules
Belmont Report - The Three Benchmark RulesBelmont Report - The Three Benchmark Rules
Belmont Report - The Three Benchmark Rules
 
One Health: Concept and applications
One Health: Concept and applicationsOne Health: Concept and applications
One Health: Concept and applications
 
Precision Medicine - The Future of Healthcare
Precision Medicine - The Future of HealthcarePrecision Medicine - The Future of Healthcare
Precision Medicine - The Future of Healthcare
 
Top 10 medical research interview questions and answers
Top 10 medical research interview questions and answersTop 10 medical research interview questions and answers
Top 10 medical research interview questions and answers
 
Molecular mechanisms in crpc
Molecular mechanisms in crpcMolecular mechanisms in crpc
Molecular mechanisms in crpc
 
Patient recruitment
Patient recruitmentPatient recruitment
Patient recruitment
 
Building Ethics into the Research with Vulnerable groups
Building Ethics into the Research with Vulnerable groups Building Ethics into the Research with Vulnerable groups
Building Ethics into the Research with Vulnerable groups
 
Solidarity trial - challenges and success
Solidarity trial - challenges and successSolidarity trial - challenges and success
Solidarity trial - challenges and success
 
Automate your literature monitoring for more effective pharmacovigilance
Automate your literature monitoring for more effective pharmacovigilanceAutomate your literature monitoring for more effective pharmacovigilance
Automate your literature monitoring for more effective pharmacovigilance
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
 
genetic disorder and cancer.pptx
genetic disorder and cancer.pptxgenetic disorder and cancer.pptx
genetic disorder and cancer.pptx
 
Decentralized Clinical Trials, presentaiton by Craig Lipset for mHealth Israel
Decentralized Clinical Trials, presentaiton by Craig Lipset for mHealth IsraelDecentralized Clinical Trials, presentaiton by Craig Lipset for mHealth Israel
Decentralized Clinical Trials, presentaiton by Craig Lipset for mHealth Israel
 
GCP
GCPGCP
GCP
 
Introduction to biosafety
Introduction to biosafetyIntroduction to biosafety
Introduction to biosafety
 
Developing Drugs in the New Era of Personalized Medicines
Developing Drugs in the New Era of Personalized Medicines Developing Drugs in the New Era of Personalized Medicines
Developing Drugs in the New Era of Personalized Medicines
 
Ethics in Clinical Research: Challenges and Solutions
Ethics in Clinical Research: Challenges and SolutionsEthics in Clinical Research: Challenges and Solutions
Ethics in Clinical Research: Challenges and Solutions
 

Similar to COVID-19 Biological Risk Assessment Webinar

Public health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAKPublic health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAKMADHUR VERMA
 
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, India
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, IndiaImpact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, India
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, Indiaijtsrd
 
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First EditionHA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First EditionHealth Advances
 
Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...
Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...
Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...DrHeena tiwari
 
Role of chemical engineers to combat COVID 19 Pandemic
Role of chemical engineers to combat COVID 19 PandemicRole of chemical engineers to combat COVID 19 Pandemic
Role of chemical engineers to combat COVID 19 PandemicSABARINATH C D
 
Community Medicine.ppt
Community Medicine.pptCommunity Medicine.ppt
Community Medicine.pptHamdiAlaqal
 
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in SingaporeStepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in SingaporeValentina Corona
 
Health advances covid-19_3
Health advances covid-19_3Health advances covid-19_3
Health advances covid-19_3Health Advances
 
Covid 19 emergencia Dr. Freddy Flores Malpartida
Covid 19 emergencia Dr. Freddy Flores MalpartidaCovid 19 emergencia Dr. Freddy Flores Malpartida
Covid 19 emergencia Dr. Freddy Flores MalpartidaFreddy Flores Malpartida
 
Infection control in community setting
Infection control in community settingInfection control in community setting
Infection control in community settingKaushal Goti
 
Covid-19: risk assessment and mitigation measures in healthcare and non healt...
Covid-19: risk assessment and mitigation measures in healthcare and non healt...Covid-19: risk assessment and mitigation measures in healthcare and non healt...
Covid-19: risk assessment and mitigation measures in healthcare and non healt...Ahmed Hasham
 
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2KuchealArivalagan
 
Prevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID CrisisPrevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID Crisispateldrona
 
Prevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID CrisisPrevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID Crisisclinicsoncology
 
Prevalence and determinants of distress among residents during COVID crisis
Prevalence and determinants of distress among residents during COVID crisisPrevalence and determinants of distress among residents during COVID crisis
Prevalence and determinants of distress among residents during COVID crisiskomalicarol
 
Annals of Clinical and Medical Case Reports - Acmcasereport
Annals of Clinical and Medical Case Reports - AcmcasereportAnnals of Clinical and Medical Case Reports - Acmcasereport
Annals of Clinical and Medical Case Reports - Acmcasereportsemualkaira
 

Similar to COVID-19 Biological Risk Assessment Webinar (20)

Covid-19
Covid-19Covid-19
Covid-19
 
Covid-19.pdf
Covid-19.pdfCovid-19.pdf
Covid-19.pdf
 
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAKPublic health emergencies DR. MADHUR VERMA PGIMS ROHTAK
Public health emergencies DR. MADHUR VERMA PGIMS ROHTAK
 
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, India
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, IndiaImpact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, India
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, India
 
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First EditionHA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition
HA101: Demystifying SARS-CoV-2 Testing for COVID-19-First Edition
 
64th Publication- JPBS- 7th Name.pdf
64th Publication- JPBS- 7th Name.pdf64th Publication- JPBS- 7th Name.pdf
64th Publication- JPBS- 7th Name.pdf
 
256th publication jpbs- 7th name
256th publication  jpbs- 7th name256th publication  jpbs- 7th name
256th publication jpbs- 7th name
 
Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...
Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...
Awareness And Practice Of Infection Control Protocol Amidst Covid-19 Pandemic...
 
Role of chemical engineers to combat COVID 19 Pandemic
Role of chemical engineers to combat COVID 19 PandemicRole of chemical engineers to combat COVID 19 Pandemic
Role of chemical engineers to combat COVID 19 Pandemic
 
Community Medicine.ppt
Community Medicine.pptCommunity Medicine.ppt
Community Medicine.ppt
 
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in SingaporeStepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
Stepping Forward: Urologists' Effort During the COVID-19 Outbreak in Singapore
 
Health advances covid-19_3
Health advances covid-19_3Health advances covid-19_3
Health advances covid-19_3
 
Covid 19 emergencia Dr. Freddy Flores Malpartida
Covid 19 emergencia Dr. Freddy Flores MalpartidaCovid 19 emergencia Dr. Freddy Flores Malpartida
Covid 19 emergencia Dr. Freddy Flores Malpartida
 
Infection control in community setting
Infection control in community settingInfection control in community setting
Infection control in community setting
 
Covid-19: risk assessment and mitigation measures in healthcare and non healt...
Covid-19: risk assessment and mitigation measures in healthcare and non healt...Covid-19: risk assessment and mitigation measures in healthcare and non healt...
Covid-19: risk assessment and mitigation measures in healthcare and non healt...
 
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
 
Prevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID CrisisPrevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID Crisis
 
Prevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID CrisisPrevalence and Determinants of Distress Among Residents During COVID Crisis
Prevalence and Determinants of Distress Among Residents During COVID Crisis
 
Prevalence and determinants of distress among residents during COVID crisis
Prevalence and determinants of distress among residents during COVID crisisPrevalence and determinants of distress among residents during COVID crisis
Prevalence and determinants of distress among residents during COVID crisis
 
Annals of Clinical and Medical Case Reports - Acmcasereport
Annals of Clinical and Medical Case Reports - AcmcasereportAnnals of Clinical and Medical Case Reports - Acmcasereport
Annals of Clinical and Medical Case Reports - Acmcasereport
 

More from Nimonik

Generative AI for Regulatory Analysis
Generative AI for Regulatory AnalysisGenerative AI for Regulatory Analysis
Generative AI for Regulatory AnalysisNimonik
 
Nimonik Brochure
Nimonik BrochureNimonik Brochure
Nimonik BrochureNimonik
 
ISO 37301 Compliance Management Systems
ISO 37301 Compliance Management SystemsISO 37301 Compliance Management Systems
ISO 37301 Compliance Management SystemsNimonik
 
Calgary Oil & Gas Regulatory and Standards Day January 18th 2023
Calgary Oil & Gas Regulatory and Standards Day January 18th 2023Calgary Oil & Gas Regulatory and Standards Day January 18th 2023
Calgary Oil & Gas Regulatory and Standards Day January 18th 2023Nimonik
 
Best Practices for Regulatory Change Management
Best Practices for Regulatory Change ManagementBest Practices for Regulatory Change Management
Best Practices for Regulatory Change ManagementNimonik
 
Build a business case for compliance March 2022
Build a business case for compliance March 2022Build a business case for compliance March 2022
Build a business case for compliance March 2022Nimonik
 
ESG and Compliance: Where do we go from here?
ESG and Compliance: Where do we go from here?ESG and Compliance: Where do we go from here?
ESG and Compliance: Where do we go from here?Nimonik
 
State of Compliance 2021 at Mid-Market Firms - Nimonik
State of Compliance 2021 at Mid-Market Firms - NimonikState of Compliance 2021 at Mid-Market Firms - Nimonik
State of Compliance 2021 at Mid-Market Firms - NimonikNimonik
 
ISO 19600 Section 4.5 - Know your Obligations
ISO 19600 Section 4.5 - Know your ObligationsISO 19600 Section 4.5 - Know your Obligations
ISO 19600 Section 4.5 - Know your ObligationsNimonik
 
Preparing for a Post Covid World
Preparing for a Post Covid WorldPreparing for a Post Covid World
Preparing for a Post Covid WorldNimonik
 
Identify Applicable EHS Regulatory Documents
Identify Applicable EHS Regulatory DocumentsIdentify Applicable EHS Regulatory Documents
Identify Applicable EHS Regulatory DocumentsNimonik
 
19600 Compliance Management System Guidelines
19600 Compliance Management System Guidelines19600 Compliance Management System Guidelines
19600 Compliance Management System GuidelinesNimonik
 
19600 compliance management system guidelines
19600   compliance management system guidelines19600   compliance management system guidelines
19600 compliance management system guidelinesNimonik
 
Survey results - Centrally vs Locally managed compliance
Survey results - Centrally vs Locally managed complianceSurvey results - Centrally vs Locally managed compliance
Survey results - Centrally vs Locally managed complianceNimonik
 
Continous compliance october 2019 webinar (2)
Continous compliance   october 2019 webinar (2)Continous compliance   october 2019 webinar (2)
Continous compliance october 2019 webinar (2)Nimonik
 
The not so hidden costs of non-compliance
The not so hidden costs of non-complianceThe not so hidden costs of non-compliance
The not so hidden costs of non-complianceNimonik
 
The 4 key types of regulations and how to comply (3)
The 4 key types of regulations and how to comply (3)The 4 key types of regulations and how to comply (3)
The 4 key types of regulations and how to comply (3)Nimonik
 
Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...
Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...
Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...Nimonik
 
Process Area Site Assessments techniques for the Management
Process Area Site Assessments techniques for the ManagementProcess Area Site Assessments techniques for the Management
Process Area Site Assessments techniques for the ManagementNimonik
 
Air monitoring presentation
Air monitoring presentationAir monitoring presentation
Air monitoring presentationNimonik
 

More from Nimonik (20)

Generative AI for Regulatory Analysis
Generative AI for Regulatory AnalysisGenerative AI for Regulatory Analysis
Generative AI for Regulatory Analysis
 
Nimonik Brochure
Nimonik BrochureNimonik Brochure
Nimonik Brochure
 
ISO 37301 Compliance Management Systems
ISO 37301 Compliance Management SystemsISO 37301 Compliance Management Systems
ISO 37301 Compliance Management Systems
 
Calgary Oil & Gas Regulatory and Standards Day January 18th 2023
Calgary Oil & Gas Regulatory and Standards Day January 18th 2023Calgary Oil & Gas Regulatory and Standards Day January 18th 2023
Calgary Oil & Gas Regulatory and Standards Day January 18th 2023
 
Best Practices for Regulatory Change Management
Best Practices for Regulatory Change ManagementBest Practices for Regulatory Change Management
Best Practices for Regulatory Change Management
 
Build a business case for compliance March 2022
Build a business case for compliance March 2022Build a business case for compliance March 2022
Build a business case for compliance March 2022
 
ESG and Compliance: Where do we go from here?
ESG and Compliance: Where do we go from here?ESG and Compliance: Where do we go from here?
ESG and Compliance: Where do we go from here?
 
State of Compliance 2021 at Mid-Market Firms - Nimonik
State of Compliance 2021 at Mid-Market Firms - NimonikState of Compliance 2021 at Mid-Market Firms - Nimonik
State of Compliance 2021 at Mid-Market Firms - Nimonik
 
ISO 19600 Section 4.5 - Know your Obligations
ISO 19600 Section 4.5 - Know your ObligationsISO 19600 Section 4.5 - Know your Obligations
ISO 19600 Section 4.5 - Know your Obligations
 
Preparing for a Post Covid World
Preparing for a Post Covid WorldPreparing for a Post Covid World
Preparing for a Post Covid World
 
Identify Applicable EHS Regulatory Documents
Identify Applicable EHS Regulatory DocumentsIdentify Applicable EHS Regulatory Documents
Identify Applicable EHS Regulatory Documents
 
19600 Compliance Management System Guidelines
19600 Compliance Management System Guidelines19600 Compliance Management System Guidelines
19600 Compliance Management System Guidelines
 
19600 compliance management system guidelines
19600   compliance management system guidelines19600   compliance management system guidelines
19600 compliance management system guidelines
 
Survey results - Centrally vs Locally managed compliance
Survey results - Centrally vs Locally managed complianceSurvey results - Centrally vs Locally managed compliance
Survey results - Centrally vs Locally managed compliance
 
Continous compliance october 2019 webinar (2)
Continous compliance   october 2019 webinar (2)Continous compliance   october 2019 webinar (2)
Continous compliance october 2019 webinar (2)
 
The not so hidden costs of non-compliance
The not so hidden costs of non-complianceThe not so hidden costs of non-compliance
The not so hidden costs of non-compliance
 
The 4 key types of regulations and how to comply (3)
The 4 key types of regulations and how to comply (3)The 4 key types of regulations and how to comply (3)
The 4 key types of regulations and how to comply (3)
 
Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...
Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...
Comprehensive Compliance for Environmental, Safety, Quality Requirements in C...
 
Process Area Site Assessments techniques for the Management
Process Area Site Assessments techniques for the ManagementProcess Area Site Assessments techniques for the Management
Process Area Site Assessments techniques for the Management
 
Air monitoring presentation
Air monitoring presentationAir monitoring presentation
Air monitoring presentation
 

Recently uploaded

Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17Celine George
 
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxContemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxRoyAbrique
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsKarinaGenton
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...M56BOOKSTORE PRODUCT/SERVICE
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 

Recently uploaded (20)

Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17
 
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptxContemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
Contemporary philippine arts from the regions_PPT_Module_12 [Autosaved] (1).pptx
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its Characteristics
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 

COVID-19 Biological Risk Assessment Webinar

  • 1. Biological Threats: Dealing with COVID in the Workplace June 2020 Presenter: Doug Kube, EP, CHSC dougkube@outlook.com
  • 2. Introductions 2 Presenter & Facilitator:  Doug has worked for 30 years' in safety, occupational and public health.  He has worked in a variety of sectors including pharmaceutical, food, aviation/aerospace, courier/mail, chemical and consulting engineering.  Doug was Senior Director, Health, Safety & Environment at Sanofi Pasteur Toronto where he was responsible for the biological safety and bio- containment program at its containment level 2 and 3 vaccine manufacturing, research and development site.  He was part Air Canada’s team that led the response to the 2010 H1N1 influenza pandemic and part of Purolator’s 2003 SARS response team.  He has completed post-graduate courses in High Level Biocontainment for Healthcare Facilities at University of Nebraska, Epidemics: Dynamics of Infectious Diseases at Penn State University, Emerging Infectious Diseases at Johns Hopkins Bloomberg School of Public Health and Epidemiology at University of Ottawa. Doug Kube, EP, CHSC dougkube@outlook.com Ph. 705-994-7053
  • 3. Presentation Overview We will cover the following:  Recognizing threats of COVID-19 and return to work  Preventing workplace outbreaks, work refusals or disruptions and assuring compliance  Benefits of a risk management approach  Biological safety and risk assessment fundamentals  COVID-19 Biological Risk Assessment Tool for scenarios associated with specific workplaces and jobs 3
  • 4. 4
  • 5. 5 COVID-19 Safety Plan Does your plan include all these controls? • Work from home • Postpone projects • Stop meeting face to face • Physical distancing of 2 m • Wear face coverings or masks • Medical screening of visitors & workers • Reschedule unnecessary visits • Train everyone on possible hazards • Train people on how to keep surface clean • Limit the # of people working in one space • Have everyone wash their hands • Reposition workstations to increase distances • Control # of people in workplace at one time, who they speak to, what they handle • Clean and disinfect workplace thoroughly and frequently • Keep COVID-19 awareness, safety talk, while maintaining a safe physical distance 5
  • 6. Cost of getting it wrong? • Death (Global 361,270, U.S. 101,706, Cda 6,982)1 • Pain and suffering (Ontario 1,613 intensive care) • Illness & serious illness (Hospitalized: NY 78,043, ON 8,152) • Business interruption (40% Canadian retailers closed) • Reduced morale • More regulatory scrutiny, non-compliance • Corporate reputation, employee and customer confidence • Cost of workers compensation claims • Divert management attention • Lost business opportunity 1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6, taken 29May2020
  • 7. Benefits of Risk Management Approach to COVID-19  ‘Stress test’ existing COVID-19 safety plans  Workplace-specific assessment and inventory of:  Key jobs/positions of concern  Work locations with greatest risk  Establish organizational risk profile and risk tolerance  Enhanced, targeted risk controls to reduce transmission  Increase organizational capacity to monitor and manage  Confidence to employees, managers, Union, Boards  Support existing crisis and business continuity plans  Ensure compliance and due diligence 7
  • 8. 8 COVID-19 Biological Risk Assessment: Training & Risk Assessment 1. Pandemic Status 2. Biosafety Fundamentals 3. Risk Assessment Basics 4. Risk Assessment Tool Virtual Risk Assessment Workshop • Routes of transmission • Decontamination and disinfection • ISO 31000 standard for risk management, • Identifying risk treatment and controls • Using the Excel Tool to analyze and evaluate risk • Job–specific, targeted risk controls • Facilitate virtual, online assessment with Tool • Analyze existing controls and evaluate effectiveness • Identify additional preventative and protective measures • Current pandemic situation • Implications for business
  • 9. 9 Pandemic Status & Update Case Demographic Distribution https://ourworldindata.org/mortality-risk-covid, taken 29May2020 Case Fatality Rate by Age  Case distribution equal in working adults  Older age, especially > 65 yrs and people with comorbidities appear more likely to develop an infection and severe symptoms and be at risk for death1  In the U.S., obesity appears to be emerging as a risk factor, BMI ≥ 30, in nearly 1/2 of hospitalized patients1  85% of Canadian cases in Ontario & Quebec  Community-specific spread (hot spots) 1. Johns Hopkins ABX Guide, Paul G. Auwaerter, M.D., Coronavirus COVID-19 (SARS-CoV-2), Updated: May 23, 2020
  • 10. Severe Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) 10 1. Ontario Health, Epidemiologic Summary, Confirmed cases (n=22,957) of COVID-19 by severity: Ontario, January 15, 2020 to May 17, 2020 2. Johns Hopkins ABX Guide, Paul G. Auwaerter, M.D., Coronavirus COVID-19 (SARS-CoV-2), Updated: May 23, 2020  New strain not previously in humans  Enveloped, positive-sense single-stranded RNA viruses  Incubation period (exposure to symptom onset) 4 to 6 days  Infectious 1 to 3 days before symptoms appear  Peak viral load in pharynx ~4 days after infected  Health effects:  Older and those with underlying medical condition = high risk,  95% of deaths in group 60+ years of age1  Many infected have no symptoms (studies suggest up to 50%)2
  • 11. Biological Safety Fundamentals Routes of Transmission  Droplets-borne: via droplets from the nose or mouth spread when infected person sneezes or coughs  Fomite: Indirect contact via droplet contaminated surfaces. Touch surface, then eyes, nose or mouth  Detectable on plastic and steel up to 3 days, cardboard 1 day, copper 4 hours.  Virus load reduces over time (half-life 5-6 hours)  SARS-CoV-2 is an enveloped virus, therefore highly susceptible to disinfectants  Aerosol spread could occur, mostly in hospitals1 1. Johns Hopkins ABX Guide, Paul G. Auwaerter, M.D., Coronavirus COVID-19 (SARS-CoV-2), Updated: May 23, 2020
  • 12. Biological Safety Fundamentals What Increases Transmission Risk?  Factors that affect risk: 1. People close to one another 2. Many people together (group gatherings) 3. Duration of interaction  Successful Infection = Exposure to Virus x Time 4. Type of activity  Talking quietly vs. cheering/shouting at sports event 5. Physical environment  Layout? Degree of protection? Separation? Air flow direction and volume? Air purification systems? Close contact means: a face-to-face conversation for 15 minutes, or being in the same room for 2 hours (Source: Ontario Self-Assessment website https://covid-19.ontario.ca/self-assessment/, taken 08May2020)
  • 13. Biological Safety Fundamentals Decontamination & Disinfection  Enveloped virus = Highly susceptible to disinfectants  Critical parameters for chemical disinfection: Type, concentration, contact time and temperature  Proven chemical disinfectants: • 0.05% sodium hypochlorite (household bleach), dilute 1:100 • Alcohol (ethanol) at least 70% • Hydrogen peroxide 0.5% • Benzalkonium chloride >0.05% (less effective)  Ultraviolet (UVC) light disinfection (30 mJ/cm2)* 13 * N95 Filtering Facepiece Respirator Ultraviolet Germicidal Irradiation (UVGI) Process for Decontamination and Reuse, University of Nebraska, Version Update 4/10/2020 Refer to manufacturer's specifications and instructions for proper concentration, contact time and temperature.
  • 14. Risk Assessment Fundamentals We will cover the following:  Risk management based on ISO 31000 standard  Conducting risk assessments  Assessing biological and occupational health exposures  Ascertaining risk tolerance  Identifying risk treatment and controls 14
  • 15. Key Definitions  Hazard - Source with a potential to cause injury and ill health. (ISO45001)  The SARS-CoV-2 virus is a hazard  Risk - The effect of uncertainty on objectives (ISO31000)  Assessment of the consequences (illness) expressed in terms of probability (likely, unlikely) and severity (mildly sick, death) is the risk.  Becoming ill is one of the consequences of the hazard  Risk Management - Coordinated activities to direct and control an organization with regards to risk (ISO31000)  The identification, analysis and elimination, and/or mitigation to an acceptable level of risk 15
  • 16. 16 Risk Management Why is it Important?  One way to protect employees and the business  Key part of H&S Management System  Helps ensure business continuity  Enables business to re-open, re-start or sustain operations  Compliance requirement:  WorkSafe British Columbia requires a COVID-19 Safety Plan be posted in the workplace. “Step 1: Assess the risks at your workplace”  Ontario “The employer is required to take every reasonable precaution … and do a risk assessment to determine what parts of the jobsite and what other workers the affected worker would have had contact with.”  U.S. OSHA: "The employer shall assess the workplace to determine if hazards are present, or are likely to be present, which necessitate the use of personal protective equipment (PPE)."
  • 17. Health & Safety Programs Why do they need risk assessments? Risk Assessments:  Create awareness of hazards and risk.  Identify who may be at risk.  Prioritize risks and control methods.  Determine the overall risk management plan an organization should develop.  Determine if existing mitigation measures are adequate or if additional measures are needed.  Determine training needs. 17
  • 18. Team!  A team approach is needed  Leader will facilitate the process  Team needs to include subject matter participants with knowledge and experience necessary to assess the activity and risks  Team provides expertise on the work and work areas and envision ‘hazardous situations’  Need more than H&S expertise  Decisions to accept of residual risk may need to be escalated to “decision maker” 18
  • 19. 19 Define the risk index and tolerability Define the level of probability Define the level of severity Is the risk index acceptable? Can the risk be eliminated? Can the risk be mitigated? Can the residual risk be accepted? (if any) Take action and continue the operation Health & safety concern is perceived Identify hazards/consequences and assess risks NO NO NO Cancel the operation YES Take action and continue the operation YES Take action and continue the operation YES YES Risk Identification Risk Analysis Risk Evaluation Risk Treatment (6.5) RiskAssessment(6.4) Risk Management as a Process
  • 20. Risk Management Risk Evaluation & Tolerance Undesirable Improvable Acceptable Unacceptable and MUST have more treatment or controls Acceptable with current controls but recommend more treatment. Acceptable as it currently stands, no further action As Low As Reasonably Practicable
  • 21. Risk Treatment & Controls  Risk Treatment: Process to modify risk  Control: Measure that maintains or modifies risk 1. avoiding the risk by not to starting or continuing with the activity that gives rise to the risk (no face-to-face meetings, use Zoom or MS Teams); 2. removing the risk source (disinfecting surface); 3. changing the likelihood (shop less frequently); 4. changing the consequences (early medical care); 5. sharing the risk (buying insurance); and 6. retaining the risk by informed choice.
  • 22. The Goal & “The Gold” Risk Controls Technical (engineering controls & PPE)  HEPA air filtration of, plastic shields on cashier stations, one-way aisle, surgical mask Organizational / Administrative  Physical distancing, personnel screening, hygiene (cleaning & disinfection, handwashing) close areas, work at home, Zoom meetings Human / Behavioural  Report when ill, sneeze/cough etiquette, train, personnel screening, culture (managerial safety visits, procedure use & adherence) Technical (Engineering Controls) Human (Behavioural Controls) Organizational (Administrative Controls)
  • 23. 5 Step Process & Methodology Questionnaire Obtain site-specific details, job risks, community/worker incidence, trends, plan and precautions implemented to date Environmental Scan Review current outbreak, known transmission dynamics, geographic distribution Interview Obtain site details, understand work environment, stakeholders, local guidance issued & actioned to date Training Prepare participants with knowledge and understanding to participate Identify jobs and potential hazard situations and threats to health, safety, business continuity Virtual, online Risk Assessment Analyze chosen jobs, specific to exposure and vulnerability Use spreadsheet tool to evaluate, consider existing controls Enable team to identify targeted, additional preventative and protective measures
  • 24. 24  RISK EVALUATION to support decision making  GREEN = Acceptable, YELLOW = Improvable, RED = unacceptable,  Do nothing, maintain existing controls, implement additional controls, stop activity  Continual improvement: validate or assess the value of additional and new controls Output  RISK TREATMENT & CONTROLS: Additional and sustainable actions identified and documented that can eliminate, reduce or mitigate the risk  PREVENTION: avoid or reduce likelihood of exposure, and  REDUCTION: reduce severity or impact, mitigate business losses  Communication tool for case investigations, contact tracing, refusals, grievances Severity Exposure Frequency Probability of Scenario Risk Score HSE CONCLUSION COMMENTS ACTION PLAN / ADDITIONAL RISK TREATMENT & CONTROLS 1. First Aid 5. Disabling illness (lost time) 15. Illness with medical treatment; Minor business impact 25. Illness with hospitalization; Significant business impact 50. Death; Major business impact 100. Multiple deaths; catastrophic 0.5. Very rarely 1. Rarely (known_ 2. Unusual (1/mo-1/yr) 3. Occassional (1/wk-1/mo) 6. Frequently (~1/day) 10. Continuously, many/day 0.1 Practically impossible 0.5 Extremely remote 1. Remotely possible 3. Would be unusual 6. Quite possible (50/50) 10. Expected Calculated. (Risk Level with consideration for existing controls). Risk < 90 = Acceptable 90 - 270 = Improvable > 270 = Undesirable/Action! (Clarify any existing controls and note any relavent facts or assumtions that may help in identifying risk treatment or controls.) (List and describe any additional actions or risk treatment (the process to modify risk) that can be taken to eliminate, reduce or mitigate the risk. Risk Treatment or controls should consider preventing (avoiding or reducing likelhood of exposure) and reducing the severity. Ensure you review all Proactive and Preventative Measures (Technical, Organizational and Human) listed in tab enstitled "Scoring Guide & Measures") 15 3 6 270 Stores are encouraging customers to 'tap' and signs posted indicating cash transactions not recommended. Cashiers are told to disinfect station, belt and ATM every hour. But, hourly disinfection doesn't address touching grocery items. May need to consider accomodating vulnerable or at-risk workers. Improvable 1. Document COVID-19 safety plan to comply with provincial requirements. 2. Develop SOP for PPE, require cashiers to wear gloves when touching grocery items. 3. Develop cleaning/disinfection procedures for store and include cash stations. 4. Manager Safety Visits by managers to verify controls are implemented, talk to employees about their concerns, coach them and provide caring safety culture. 5. Implement written SOP on safe handling/scanning of grocery items and include H&S precautions/controls included from this risk risk assessment. 6. Implement HuP Tool - Procedure Use & Adherence with managers conducting hourly observations. 7. Implement process for more active personnel monitoring, screening and assessment. ASSUMPTIONS: Severity score (25) based on scenario of serious illness requiring hospitalization. NOTE: 4 vulnerable or at-risk employees known to work in area. Exposure score (2), assuming that although cashier may touch items constantly, having an infected customer and touching his/her items would be far less frequent or likely. Probability score (3) assumes its unlikely the scenario would occur that leads to hospitalization.  Prioritize and ensure regulatory compliance = Due Diligence
  • 25. THANK YOU! For more information of assistance: Doug Kube, EP, CHSC dougkube@outlook.com Ph. 705-994-7053